Institutional Biosafety Committee
September 11, 2026
12:00PM – 1:00PM
Teleconference

Minutes

Voting Members Present: Ami A. Patel, Alan Schmaljohn, Elizabeth Bramhall, Jennifer Johnson, John O'Neill, Irina Luzina, Janna Barcelo, Matthew Frieman, Sherry Bohn, Jessie Duggan, Matthew Fischer

Voting Members Absent: Brian Taylor, Marianne Cloeren, Karen Scanlon, Ron McNeil, Melissa Morland, Anthony Kim, Joseph Gillespie, Sammy Almashat, Robert Ernst, Ciaran Skerry, Alfredo Garzino-Demo

Other Person(s) Present: Andrew Ayers

Staff Present: Matthew Fischer, John O'Neill, Holda Ramos

1 Vote on Last Meeting's Minutes

Institutional Biosafety Committee meeting on 8/7/2026
Votes to approve minutes: 11, Disapprove: 0, Abstain: 0

2 New Business

This meeting of the IBC is open to the public pursuant to the NIH Guidelines, Section IV-B-2-a-(6).

- The NIH Office of Science Policy released a "Draft NIH Policy for Research Involving Biohazards" on August 19th. This policy is the planned modernization effort to replace the "NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules" that governs the IBC. It is open for comment through October 19th. Changes include:
    - Some things currently with Full Committee Review will move to Delegated Member Review
    - Some things currently with Administrative Approval will move to Full Committee Review
    - Some things currently not requiring an IBC protocol will move to needing one
    - IBC minutes will need to use a greatly expanded template
    - Incident reports will need to be published on a public website
    - Protocols must close and be submitted anew every three years.
    - Post Approval Monitoring is required.
- UMB and UMD are forming a joint task force to respond to the White House Policy on "Dangerous Gain of Function" and Draft NIH Policy
- Our next meeting is scheduled for Friday, October 2nd.
- Member issues

- ASM Maryland is hosting a technical seminar dinner meeting at UMBC entitled "Bacterial Adaptations When Antibiotic - Immunity Collaborations Fail" on October 14th
- ChABSA is hosting a technical seminar dinner meeting in Ellicott City entitled "The Great BSL-3 Design Debate: If I Designed A Laboratory Today, What Would Matter Most?" on September 16th

3 Reportable Incidents

- We had one reportable incident on September 1st in which a researcher was bitten by a mouse infected with recombinant AAV-HBV. This was sent to the NIH Office of Science Policy on September 3rd. No response has been received yet.
- No additional reportable incidents occurred this month.

4 Select Agent Program Oversight

- Our registration renewal was accepted on August 27th. It is good for three years, expiring on August 27, 2029.

5 Modification Discussions

Short Title:	Screening of BSL2 viruses with anti-viral compounds
Investigator:	Matthew Frieman
ID:	IBC-00002948
Analyst:	John O'Neill
VA-Related:	No
Discussion:	This modification involves the use of recombinant, replication-competent VSV in mammalian cells and animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-3-a using BSL-2/ABSL-2 facilities and practices. This modification also involves the use of plasmids in mammalian cells. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-F-8 Appendix C-1 using BSL-2 facilities and practices. The committee discussed that the tropism is more restricted for the VSV, but that is still an "alteration of tropism." The following modifications are required to secure approval: 1) Confirm or update personnel; 2) Update IACUC information; and 3) Upload a document that explains the change in tropism for VSV.
Motion:	RMSA
Vote:	For: 10, Against: 0, Abstained: 0 , Conflict of Interest: 1 (Matthew Frieman), Absent: 0

Short Title:	Development, Validation, and Manufacturing of genetically modified human T- and CD34+ cells
Investigator:	Kim Hankey
ID:	IBC-00006199
Analyst:	Holda Ramos
VA-Related:	No

Discussion:	This modification involves the use of recombinant lentivirus in human cells. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a and is approved using BSL-2 facilities and practices with sharps precautions.
Motion:	Approve the Modification
Vote:	For: 11, Against: 0, Abstained: 0, Conflict of Interest: 0

Short Title:	Engineering adenoviral vectors as vaccines for infectious disease
Investigator:	Lynda Coughlan
ID:	IBC-00005922
Analyst:	John O'Neill
VA-Related:	No
Discussion:	This modification involves the use of live attenuated A/Ann Arbor/6/1960 influenza virus reassortants in mammalian and avian cells and embryonated chicken eggs. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-7 and is approved using BSL-2 facilities and practices.
Motion:	Approve the Modification
Vote:	For: 11, Against: 0, Abstained: 0, Conflict of Interest: 0

Short Title:	Mechanisms of fate determination in peripheral T cells
Investigator:	Nevil Singh
ID:	IBC-00002339
Analyst:	Holda Ramos
VA-Related:	No
Discussion:	This modification involves the use of a recombinant MSCV vector and lentivirus in human and murine cells which will be used in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a and is approved using ABSL-2 facilities and practices with sharps precautions.
Motion:	Approve the Modification
Vote:	For: 11, Against: 0, Abstained: 0, Conflict of Interest: 0

Short Title:	Molecular and Functional Studies of Depression and Addiction on Brain
Investigator:	Mary Kay Lobo
ID:	IBC-00001687
Analyst:	John O'Neill
VA-Related:	No
Discussion:	This modification involves the use of recombinant AAV in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a using ABSL-1 facilities and practices. The following modifications are required to secure approval: 1) Update personnel and 2) Update IACUC information.
Motion:	RMSA
Vote:	For: 11, Against: 0, Abstained: 0, Conflict of Interest: 0

Short Title:	Engineering Plasmodium parasites to study malaria biology and host responses
Investigator:	Hardik Patel
ID:	IBC-00008704
Analyst:	Holda Ramos
VA-Related:	No
Discussion:	This modification involves the use of plasmids in *Plasmodium yoelii* which will be used in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a using BSL-1/ABSL-1 facilities and practices. The following modifications are required to secure approval: 1) Update personnel, 2) Clarify species of plasmodium being used in the study in the infectious microorganism table, and 3) Update the NIH guidelines applicable to the research.
Motion:	RMSA
Vote:	For: 11, Against: 0, Abstained: 0, Conflict of Interest: 0

Short Title:	Dissecting Neural Circuits of Learning and Emotion
Investigator:	Barbara Juarez
ID:	IBC-00007058
Analyst:	John O'Neill
VA-Related:	No
Discussion:	This modification involves the use of recombinant AAV in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a and is approved using ABSL-1 facilities and practices.
Motion:	Approve the Modification
Vote:	For: 11, Against: 0, Abstained: 0, Conflict of Interest: 0

Short Title:	Molecular and neural circuit basis of craniofacial pain
Investigator:	Man-Kyo Chung
ID:	IBC-00001592
Analyst:	Holda Ramos
VA-Related:	No
Discussion:	This modification involves the addition of two recombinant AAV constructs which will be used in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a using ABSL-1 facilities and practices. The following modifications are required to secure approval: 1) Update personnel and 2) Update IACUC information.
Motion:	RMSA
Vote:	For: 11, Against: 0, Abstained: 0, Conflict of Interest: 0

6 RMSA Follow-Up

Short Title:	Screening of BSL2 viruses with anti-viral compounds
Investigator:	Matthew Frieman

ID: IBC-00002948
Analyst: John O'Neill
VA-Related: No
Discussion: This modification involves the use of recombinant MHV in mammalian cells. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-3-a and is approved using BSL-2 facilities and practices. The following modification/action was made to secure approval: Confirmed that the existing MHV statement is true.
Status: Approved

Short Title: *In vitro* and *In vivo* analysis of the MERS Coronavirus
Investigator: Matthew Frieman
ID: IBC-00002089
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification involves the use of recombinant VSV in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a using ABSL-2 facilities and practices. The following modifications were made d to secure approval: 1) Updated personnel, 2) Replaced outdated documents, 3) Added a description of this VSV backbone to the experimental design, and 4) Updated DURC questions to reflect the new work.
Status: Approved

Short Title: The Effects of Anesthetic and Sedative Exposure on Brain Development
Investigator: Cyrus Mintz
ID: IBC-00008968
Analyst: John O'Neill
VA-Related: No
Discussion: This protocol involves the use of recombinant MMLV in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a and is approved using ABSL-2 facilities and practices. The following modifications were made to secure approval: 1) Updated the laboratory locations section; 2) Revised the statement regarding pathogenicity of MMLV; and 3) Added a link to VectorBuilder.
Status: Approved

Short Title: Mechanisms of antimicrobial and anticancer activities of Interferon-stimulated genes.
Investigator: Saumendra Sarkar
ID: IBC-00008070
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification involves the use of plasmids in mammalian cells which will be engrafted in animals. This work is classified by the NIH Guidelines for Research with

Recombinant or Synthetic Nucleic Acids as III-D-4-a and is approved using ABSL-2 facilities and practices. The following modification was made to secure approval: Added the biosafety cabinet used in the animal facility.

Status: Approved

Short Title: Development, Validation, and Manufacturing of genetically modified human T- and CD34+ cells

Investigator: Kim Hankey

ID: IBC-00006199

Analyst: Holda Ramos

VA-Related: No

Discussion: This modification involves the use of recombinant lentivirus in human cells. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-1-a and is approved using BSL-2 facilities and practices with sharps precautions. The following modification was made to secure approval: The lay abstract was rewritten so that it can be understood by non-scientists..

Status: Approved

Short Title: White matter repair by transplanted glial progenitors guided by multimodality imaging

Investigator: Piotr Walczak

ID: IBC-00007091

Analyst: John O'Neill

VA-Related: No

Discussion: This modification involves the use of recombinant AAV in animals. This work is classified by the NIH Guidelines for Research with Recombinant or Synthetic Nucleic Acids as III-D-4-a and is approved using ABSL-1 facilities and practices. The following modification was made to secure approval: Updated the host species for the new experiment to match the animal protocol.

Status: Approved

7 Periodic Reviews of Protocols with Recombinant or Synthetic Nucleic Acid Moledules

Short Title: Immunopathogenesis of Infectious Diseases

Investigator: Joao Pedra

ID: IBC-00002247

Analyst: Holda Ramos

VA-Related: No

Discussion: This modification has been administratively approved for the use of non-recombinant *Rickettsia parkeri* using ABSL-2 facility and practices.

Short Title: Role of Lipid metabolic signatures in induced pluripotent stem cell derived AD neurons.

Investigator: Robin Roychaudhuri

ID: IBC-00008072

Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Fish immune response to M. marinum infection and genetic analysis of fish muscle development and disease
Investigator: Shaojun Du
ID: IBC-00001186
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Animal Models in Cortical Dysplasia
Investigator: Peter Crino
ID: IBC-00003858
Analyst: Holda Ramos
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Tissue–specific delivery of nitroxide imaging probes for Electron Paramagnetic Resonance Imaging (EPRI)
Investigator: Joseph Kao
ID: IBC-00003567
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Mechanism of Rickettsia-Host-interaction (BSL-2)
Investigator: Mohammed Rahman
ID: IBC-00007650
Analyst: Holda Ramos
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: HIV-1 mediated Pathophysiology
Investigator: Chozha Rathinam
ID: IBC-00003929
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Inhibition of Innate Immune Signaling by SARS, MERS, HKU4 and HKU5 Coronavirus Proteins
Investigator: Matthew Frieman
ID: IBC-00000315
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Analysis of Animal Viromes
Investigator: Matthew Frieman
ID: IBC-00001349
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Blood Flow Control in Heart
Investigator: W. Jonathan Lederer
ID: IBC-00008572
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: IBC: 2478GCCC: A Phase 2 of Olvi-Vec + Pembrolizumab Compared with Docetaxel in Patients w/ NSCLC
Investigator: Samuel Rosner
ID: IBC-00008080
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Production of ETEC and Salmonella antigens from non-pathogenic *E. coli* expression vectors, and *S. aureus* capsule polysaccharides from wild-type strains
Investigator: Scott Baliban
ID: IBC-00003044
Analyst: Holda Ramos
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: HK Delivery of Nucleic Acids
Investigator: Archibald Mixson
ID: IBC-00001842
Analyst: John O'Neill

VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Biofilm studies
Investigator: Mary Ann Rizk
ID: IBC-00000578
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Biofilm Studies
Investigator: Janette Harro
ID: IBC-00000040
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Role of RGC-32 in gliosis
Investigator: Horea Rus
ID: IBC-00002541
Analyst: Holda Ramos
VA-Related: Yes
Discussion: There have been no substantive changes to this protocol submission.

Short Title: IBC Submission: RPower-HCC RP2-003 GCCC2350
Investigator: Hyun Kim
ID: IBC-00007348
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Candida albicans-Staphylococcus aureus Mixed-Species Biofilms
Investigator: Janette Harro
ID: IBC-00000172
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: IBC Submission: 2320GCCC: Expanded Access Study for the Treatment of Patients with Commercially OOS Brexucabtagene Autoleucel
Investigator: Aaron Rapoport
ID: IBC-00007195

Analyst: Holda Ramos
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Modulation of autoimmune processes by alteration of miRNA levels *in vivo* in rodent models and *in vitro*
Investigator: Kamal Moudgil
ID: IBC-00006038
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Vascular signaling plasticity
Investigator: Thomas Longden
ID: IBC-00006386
Analyst: Holda Ramos
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Examining the role of micro-RNAs in inflammation
Investigator: Kamal Moudgil
ID: IBC-00004429
Analyst: Holda Ramos
VA-Related: Yes
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Blood Flow in Learning and Memory
Investigator: Thomas Longden
ID: IBC-00005260
Analyst: Holda Ramos
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: HK Delivery of Nucleic Acids
Investigator: Archibald Mixson
ID: IBC-00001842
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: IBC: 2325GCCC: Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel

Investigator: Aaron Rapoport
ID: IBC-00007238
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: optogenetic and chemogenetic stimulation
Investigator: Todd Gould
ID: IBC-00003451
Analyst: John O'Neill
VA-Related: Yes
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Role of modulators of Pi/PPi in cementum formation and regeneration
Investigator: Emily Chu
ID: IBC-00006511
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Primary Chondrocyte Immortalization for Drug Screening
Investigator: Stephanie Jo
ID: IBC-00007694
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Validating ASCT2 for the Treatment of Chronic Postsurgical Pain
Investigator: Ohannes Melemedjian
ID: IBC-00005906
Analyst: John O'Neill
VA-Related: No
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Roles of circHIPK3 and HuR in aging gut barrier function
Investigator: Lan Xiao
ID: IBC-00007920
Analyst: John O'Neill
VA-Related: Yes
Discussion: There have been no substantive changes to this protocol submission.

Short Title: Cloning and characterization of immune genes from non-mammalian species

Investigator: Helen Dooley
ID: IBC-00003926
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification has been administratively approved for changes in personnel.

Short Title: Investigation of host immune response to Clostridioides difficile infection and development of immunotherapies
Investigator: Hanping Feng
ID: IBC-00001771
Analyst: John O'Neill
VA-Related: No
Discussion: This modification has been administratively approved for updates to biosafety cabinet certification dates.

Short Title: Efficacy of AdV.C3.tat-HIV-BoxA to protect in a murine model of CCI-injury
Investigator: Prajwal Ciryam
ID: IBC-00008725
Analyst: John O'Neill
VA-Related: No
Discussion: This modification has been administratively approved for changes in personnel.

Short Title: Mechanisms of fate determination in peripheral T cells
Investigator: Nevil Singh
ID: IBC-00002339
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification has been administratively approved for changes in personnel.

Short Title: Cellular Immunotherapy/Immunomonitoring
Investigator: Tim Luetkens
ID: IBC-00006040
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification has been administratively approved for changes in personnel.

Short Title: Long-term Inhibition of HIV transcription by targeting cellular CDK9 *in vivo*
Investigator: Alonso Heredia
ID: IBC-00003501
Analyst: Holda Ramos
VA-Related: No

Discussion: This modification has been administratively approved for an update to experiment descriptions using previously approved vectors. There is no significant change to the risk assessment.

Short Title: Co-Targeting IL-6 and CDK4/6 Pathways as a Novel Approach of Preventive Therapy for Triple-Negative Breast Cancer
Investigator: Jiayuh Lin
ID: IBC-00006504
Analyst: Holda Ramos
VA-Related: Yes
Discussion: This modification has been administratively approved for clarification of cell lines and update of the IACUC protocol number.

Short Title: Animal Models in Cortical Dysplasia
Investigator: Peter Crino
ID: IBC-00003858
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification has been administratively approved for changes in personnel.

Short Title: Viral Pathogenesis and Immunotherapy
Investigator: Lishan Su
ID: IBC-00005983
Analyst: John O'Neill
VA-Related: No
Discussion: This modification has been administratively approved for an update to the risk assessment.

Short Title: Ultrasound-Mediated Microbubble Coupled Plasmid sFlt-1 or VEGF Gene Delivery in the Pregnant Baboon and offspring.
Investigator: Graham Aberdeen
ID: IBC-00001512
Analyst: John O'Neill
VA-Related: No
Discussion: This modification has been administratively approved for a change in personnel.

Short Title: Cancer Biology and Novel Agents in Lung Cancer
Investigator: John Schmitz
ID: IBC-00007728
Analyst: Holda Ramos
VA-Related: No
Discussion: This modification has been administratively approved for changes in personnel.

Short Title:	Regulatory processes of voltage gated calcium channels
Investigator:	Ivy Dick
ID:	IBC-00003852
Analyst:	Holda Ramos
VA-Related:	No
Discussion:	This modification has been administratively approved for changes in personnel.

Short Title:	Long-term Inhibition of HIV transcription by targeting cellular CDK9 *in vivo*
Investigator:	Alonso Heredia
ID:	IBC-00003501
Analyst:	Holda Ramos
VA-Related:	No
Discussion:	This modification has been administratively approved for changes in personnel.